A director at Billerud AB bought 3,700 shares at 100.900SEK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
The Q1 reporting season is in full swing, with results from Catena, Entra, Pandox and Wihlborgs in the past week. In addition, Aurora Eiendom announced a proposal to delist from Euronext Growth Oslo. The weighted-average implied EBITDA yields on the stocks we cover are 5.00% for 2025e and 5.31% for 2026e.
The Q1 results missed our expectations and consensus, mainly on weakness in the Brussels hotel market. Following the report and given recent macro trends, we have cut our EPS by c4–5% over our forecast period, and our NAV-based target price to SEK200 (215). However, given the stock is still trading at a significant discount to NAV, and the implied EBIT yield remains attractive, we have upgraded to BUY (HOLD).
Although Q1 earnings were slightly shy of our forecast, we believe the results support our investment case. In our view, Billerud has good pricing power, especially in the US, where the market is highly consolidated and the overall earnings outlook for Q2 remains solid thanks to healthy orderbooks. Our 2025–2026e EBITDA is largely unchanged, and we reiterate our BUY and SEK130 target price.
After a series of negative earnings surprises, the Q1 results exceeded our expectations, mainly on progress in the key Consumer Packaging division. In addition, we found it reassuring that management reiterated that the forestry asset sale is ongoing, with completion expected before end-H1. We have made limited forecast changes, and reiterate our BUY and EUR12 target price.
The markets were much quieter following the Easter break, with limited news; however, the names we cover saw their shares up 2.6% on average, with Atrium Ljungberg (7.1%), SBB (7.1%) and Pandox (4.8%) the top performers. JM released its Q1 results and we reiterated our BUY, believing it has passed the earnings trough, while we reiterated our HOLDs on Corem and Fabege following their quarterly reports. The weighted-average implied EBITDA yields on the stocks we cover are 5.04% for 2025e and 5.34%...
Q1 EBIT was 4% below our estimate and Infront consensus, while EPS fell well short in percentage terms due to a low nominal figure. KPIs did not recover as much as we expected, although JM reiterated its target to increase housing starts to 3,800 units p.a., citing macroeconomic conditions as a key factor. Given the current market outlook, we believe the company has passed the trough on EPS, as we expect starts and sales to recover in late 2025 and 2026. We reiterate our BUY and target price of ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.